Developing targeted therapies for neuroinflammatory diseases caused by autoantibodies.
Official title: Antigen-directed therapies for autoantibody associated neuroinflammatory diseases.
Funded at University of California, San Francisco · NIH-10973347 · Data updated 2026-11-12
This study is looking for specific antibodies that might be causing neuroinflammatory diseases, and it aims to develop new treatments that can directly target the harmful cells involved, helping people who are affected by these conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | December 15, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $2,098,085 |
| NIH project number | 1RM1NS138808-01 |
| Project ID | NIH-10973347 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with neuroinflammatory diseases associated with autoantibodies.
✕Less likely to help
Patients with neuroinflammatory diseases not linked to autoantibodies may not benefit from this research.
What this research studies
This research focuses on identifying autoantibodies that attack cell surface antigens and may cause neuroinflammatory diseases. By using advanced techniques like single-cell sequencing, the team will create human monoclonal antibodies that can be tested in animal models. These models will help in understanding the disease mechanisms and developing targeted treatments, including engineered T cells and antibodies that specifically target the harmful B cells producing these autoantibodies. The goal is to create effective therapies that can directly address the underlying causes of these diseases.
Why it matters
Potential benefit: If successful, this research could lead to new, targeted treatments for patients suffering from neuroinflammatory diseases linked to autoantibodies.
How similar studies have gone: Other research has shown promise in using targeted therapies for autoimmune conditions, suggesting potential success for this novel approach.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Pleasure, Samuel Jeremy — University of California, San Francisco
- Study coordinator: Pleasure, Samuel Jeremy
Related research
Other NIH-funded projects on the same topics.
-
How cancer cells use exosomes to evade the immune system
This study is looking at how cancer cells use tiny bubbles called exosomes to hide proteins that can keep your immune system from fighting the tumor, and by figuring this out, the researchers hope to help doctors understand why some people respond well to cancer treatments while others don’t, ultimately aiming to creat
-
Reducing harm from smoking using electronic cigarettes
This study is looking at whether using electronic cigarettes can be a safer option for people who smoke traditional cigarettes, by comparing the health effects and exposure to harmful substances between the two.
-
Understanding how knee pain and knee obesity and muscle loss affect knee osteoarthritis
This project looks at how knee swelling, excess knee fat, and muscle loss relate to pain and structural changes in knee osteoarthritis in adults.
-
Cutaneous opioid signals in skin inflammation
A mentor-identified clinician-researcher at UCSF is studying how natural skin opioids regulate itch and pain in inflammatory skin conditions like eczema and hidradenitis, with plans to map where these opioids come from and how they affect skin nerves.
-
Pooling international data to understand long-term bisphosphonate use and atypical femur fractures
This project combines large patient datasets from multiple countries to understand how long-term bisphosphonate use relates to rare hip and thigh bone fractures, helping doctors and patients make safer treatment choices.
-
Airway cell and immune cell talks in lung transplant failure
This grant tests how airway cells and immune cells interact to drive chronic rejection after lung transplant, with the goal of slowing or preventing scar-like damage.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.